Lv1
60 积分 2025-03-24 加入
Unraveling CD8+ T Cell Alloimmunity: Insights into the Direct Pathway of Antigen Recognition from Modern Experimental Tools
3天前
求助中
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
5天前
已完结
皖公网安备34019202002308
